Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study

Figure 1 Flow chart showing patient selection for study cohorts. COVID-19: Coronavirus disease-2019; AIH: Autoimmune hepatitis; CLD: Chronic liver disease.

Figure 2 Risk of all-cause mortality, rates of hospitalization, severe diseases, need for critical care, need for mechanical ventilation, and acute kidney injury, at 30 d from coronavirus disease 2019 diagnosis. A: Between patients with autoimmune hepatitis and patients without any pre-existing liver diseases; B: Between patients with autoimmune hepatitis and patients with pre-existing liver diseases other than autoimmune hepatitis. The numbers inside the bars represent the number of patients who developed outcomes related to the study. AIH: Autoimmune hepatitis; CLD: Chronic liver disease.